Exane Derivatives Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UBS Group
UBS
|
+$19.1M |
| 2 |
RSX
VanEck Russia ETF
RSX
|
+$14.1M |
| 3 |
iShares MSCI Turkey ETF
TUR
|
+$14M |
| 4 |
iShares MSCI South Korea ETF
EWY
|
+$10.8M |
| 5 |
iShares MSCI Thailand ETF
THD
|
+$9.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Freeport-McMoran
FCX
|
+$16.7M |
| 2 |
Rogers Communications
RCI
|
+$6.28M |
| 3 |
TechnipFMC
FTI
|
+$5.75M |
| 4 |
PepsiCo
PEP
|
+$4.71M |
| 5 |
Canadian Imperial Bank of Commerce
CM
|
+$3.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 9.52% |
| 2 | Financials | 9.27% |
| 3 | Communication Services | 8.11% |
| 4 | Technology | 7.63% |
| 5 | Materials | 6.28% |
Similar funds
Exane Derivatives's Q2 2018 Portfolio in Review
As of Q2 2018, Exane Derivatives held 710 positions worth $599M, up 20% from $500M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Exane Derivatives deployed $49.8M of net new capital in Q2 2018, opening 83 new positions and adding to 162 existing holdings. Its largest new stake was UBS Group: 1,172,516 shares worth $18.1M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 9.5% of assets, down from 9.7% a quarter earlier, followed by Financials and Communication Services.
On the sell side, the largest reduction was Freeport-McMoran, an estimated $16.7M trimmed.
- Exane Derivatives's largest Q2 2018 buy was UBS Group: 1,172,516 shares worth $18.1M.
- Exane Derivatives added most to VanEck Russia ETF in Q2 2018, an estimated $14.1M increase.
- Exane Derivatives's biggest Q2 2018 reduction was Freeport-McMoran, cutting an estimated $16.7M.
- Exane Derivatives fully exited Rogers Communications in Q2 2018, selling an estimated $6.28M.
- Exane Derivatives's ten largest holdings make up 35% of its $599M portfolio in Q2 2018.
- Exane Derivatives opened 83 new positions and closed 24 in Q2 2018.
- Exane Derivatives's portfolio value rose 20% quarter-over-quarter to $599M.
Based on Exane Derivatives's 13F filing for Q2 2018, filed 19 Jul 2018.